The ACAAI & AAAAI issue a joint position statement in support of the American Thoracic Society (ATS) Guidelines on FeNO

SOLNA, Sweden – 2 April, 2012 - Aerocrine AB (OMX Nordic Exchange: AERO)
announces that a nine-member council representing both prestigious asthma
societies, the American Academy and the American College of Allergy, Asthma and
Immunology (ACAAI and AAAAI), have published a position statement in support of
the clinical practice guideline on Aerocrine’s FeNO test as published by the
ATS.
The ATS guideline on the Interpretation of Exhaled Nitric Oxide for Clinical
Applications has now received formal recognition and support from the American
College of Allergy, Asthma, and Immunology (ACAAI) and the American Academy of
Allergy, Asthma, and Immunology (AAAAI). The endorsement by the ACAAI and AAAAI
underscores the importance of measuring FeNO to assess airway inflammation in
order to determine appropriate treatment for asthma patients. The ATS guideline,
which was published in September 2011, defines clinical situations where FeNO
testing is appropriate as well as guidelines for the interpretation of FeNO
results. The ATS guideline, now also endorsed by the AAAAI and ACAAI, notes that
FeNO testing provides valuable information to the physician that traditional
clinical tools cannot provide.

“We are pleased that all 3 societies have come
forward in support of FeNO. It provides another level of credibility to the
clinical utility and cost effectiveness of the NIOX MINO® and our ability to
help clinicians make more informed decisions,” said Scott Myers, CEO,
Aerocrine.

“Several private insurance companies wanted all three societies to
support these guidelines so this statement by ACAAI and AAAAI will now provide
the proof that clinicians see the value and want to use our test. This statement
of support will also resonate with physicians outside the US who look to other
countries for guidelines and data to improve the way they practice medicine. We
are pleased that all three societies support us in helping more physicians and
patients”, continues Scott Myers, CEO, Aerocrine.

Asthma is a complex disease
and its cost burden to society on an annual basis is over $50B in the U.S.
alone. There is no cure for asthma, current therapy is focused on controlling
the disease. Aerocrine’s NIOX MINO® FeNO monitor can help physicians identify
patients who will be responsive to treatment with anti-inflammatory medications
such as inhaled corticosteroids (ICS), and alert them to patients who are not
adhering to their treatments. Now all of the major US respiratory societies
recognize the importance of FeNO testing in managing asthma.

"FeNO
measurements enable physicians to gain a perspective of underlying airway
inflammation not otherwise possible using the traditional clinical tools of
history, physical exam, lungfunction, and quality of life assessments. This
represents a giant step along the road to improving the quality of care people
with asthma receive", said Peter Boggs, MD, FACAAI, a member of the joint
ACAAI/AAAAI committee.

“The Joint Position Statement along with the ATS
Guideline is exactly what we need to capitalize on payor coverage. It’s really
quite simple – if airway inflammation defines asthma and if airway inflammation
isn’t being measured, then how can a patient be optimally treated? Physicians
don’t manage hypertension treatment without measuring blood pressure. Why then
should asthma be managed without measuring airway inflammation?” said Kathy
Hodgdon, US Director of Sales and Marketing, Aerocrine.

For more information
regarding the ATS Guideline, visit www.thoracic.org. For more information on the
Joint Statement, visit http://acaai
-365.ascendeventmedia.com/Content.aspx?p=374

For more information,
contact:

Scott Myers, President & CEO, Aerocrine AB, Phone: +46 768
788 379

Kathy Hodgdon, Director of sales & marketing, Aerocrine Inc.,
telephone +1 (314) 566 8546

Chip Neff, President, Aerocrine Inc., telephone
+1 (919) 696 4267
About Aerocrine

Aerocrine AB is a medical technology company focused on the
improved management and care of patients with inflammatory airway diseases. As
the pioneer and leader in the technology to monitor and manage airway
inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable
fast and reliable management of airway inflammation and may therefore play a
critical role in more effective diagnosis, treatment and follow-up of patients
with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden
with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on
the Stockholm Stock Exchange on 15 June 2007. Aerocrine discloses the
information provided herein pursuant to the Securities Markets Act and/or the
Financial Instruments Trading Act. The information was submitted for publication
at 08:00 a.m. on April 2, 2012.